-
1
-
-
0345456822
-
ABT-089: An orally active cholinergic channel modulator (ChCM) with cognitive enhancing and neuroprotective activity
-
In: Becker, R., Giacobini, E., Robert, P. (Eds.), Birkhäuser, Boston
-
Arneric, S.P., Bannon, A.W., Briggs, C.A., Brioni, J.D., Buccafusco, J.J., Decker, M.W., Gopalakrishnan, M., Holladay, M.W., Kyncl, J., Lin, N.H., Marsh, K.G., Qiu, Y., Radek, R., Donnelly-Roberts, D.L., Sullivan, J.P., Williams, M., 1996. ABT-089: an orally active cholinergic channel modulator (ChCM) with cognitive enhancing and neuroprotective activity. In: Becker, R., Giacobini, E., Robert, P. (Eds.), Alzheimer's Disease: From Molecular Biology to Therapy. Birkhäuser, Boston.
-
(1996)
Alzheimer's Disease: From Molecular Biology to Therapy
-
-
Arneric, S.P.1
Bannon, A.W.2
Briggs, C.A.3
Brioni, J.D.4
Buccafusco, J.J.5
Decker, M.W.6
Gopalakrishnan, M.7
Holladay, M.W.8
Kyncl, J.9
Lin, N.H.10
Marsh, K.G.11
Qiu, Y.12
Radek, R.13
Donnelly-Roberts, D.L.14
Sullivan, J.P.15
Williams, M.16
-
2
-
-
0030726757
-
ABT-089 [3-(2-(S)-pyrrolidinylmethoxy)-2-methyl-pyridine]: III. An orally effective cholinergic channel modulator with potential once-a-day dosing and cardiovascular safety
-
submitted. in press
-
Arneric, S.P., Campbell, J.E., Holladay, M.W., Johnson, P., Lin, N.H., Marsh, K.G., Petersen, B., Qiu, Y., Roberts, E.M., Rodrigues, A.D., Sullivan, J.P., Trivedi, J., Williams, M., submitted. ABT-089 [3-(2-(S)-pyrrolidinylmethoxy)-2-methyl-pyridine]: III. An orally effective cholinergic channel modulator with potential once-a-day dosing and cardiovascular safety. Drug Development Research, in press.
-
Drug Development Research
-
-
Arneric, S.P.1
Campbell, J.E.2
Holladay, M.W.3
Johnson, P.4
Lin, N.H.5
Marsh, K.G.6
Petersen, B.7
Qiu, Y.8
Roberts, E.M.9
Rodrigues, A.D.10
Sullivan, J.P.11
Trivedi, J.12
Williams, M.13
-
4
-
-
0027275566
-
Physiological parameters in laboratory animals and humans
-
Davies B., Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research. 10:1993;1093-1095.
-
(1993)
Pharmaceutical Research
, vol.10
, pp. 1093-1095
-
-
Davies, B.1
Morris, T.2
-
5
-
-
0013809135
-
Investigation of factors influencing release of solid drug dispersed in inert matrices
-
Desai S.J., Simonelli A.P., Higuchi W.I. Investigation of factors influencing release of solid drug dispersed in inert matrices. Journal of Pharmaceutical Sciences. 54:1965;1459-1464.
-
(1965)
Journal of Pharmaceutical Sciences
, vol.54
, pp. 1459-1464
-
-
Desai, S.J.1
Simonelli, A.P.2
Higuchi, W.I.3
-
6
-
-
0025180649
-
Release of highly water-soluble medicinal compounds from inert, heterogeneous matrixes. I: Physical mixture
-
Foster T.P., Parrott E.L. Release of highly water-soluble medicinal compounds from inert, heterogeneous matrixes. I: Physical mixture. Journal of Pharmaceutical Sciences. 79:1990;806-810.
-
(1990)
Journal of Pharmaceutical Sciences
, vol.79
, pp. 806-810
-
-
Foster, T.P.1
Parrott, E.L.2
-
7
-
-
0022344635
-
A polyexponential deconvolution method. Evaluation of the 'gastrointestinal bioavailability' and mean in vivo dissolution time of some ibuprofen dosage forms
-
Gillespie W., Veng-Pedersen P. A polyexponential deconvolution method. Evaluation of the 'gastrointestinal bioavailability' and mean in vivo dissolution time of some ibuprofen dosage forms. Journal of Pharmacokinetics and Biopharmaceutics. 13:1985;289-307.
-
(1985)
Journal of Pharmacokinetics and Biopharmaceutics
, vol.13
, pp. 289-307
-
-
Gillespie, W.1
Veng-Pedersen, P.2
-
8
-
-
0344893332
-
Mechanism of sustained-action medication
-
Higuchi T. Mechanism of sustained-action medication. Journal of Pharmaceutical Sciences. 52:1963;1145-1150.
-
(1963)
Journal of Pharmaceutical Sciences
, vol.52
, pp. 1145-1150
-
-
Higuchi, T.1
-
9
-
-
0029053798
-
A new gradient matrix formulation and characterization
-
Hildgen P., McMullen J.N. A new gradient matrix formulation and characterization. Journal of Controlled Release. 34:1995;263-271.
-
(1995)
Journal of Controlled Release
, vol.34
, pp. 263-271
-
-
Hildgen, P.1
McMullen, J.N.2
-
10
-
-
0024323082
-
Hydroxypropylmethylcellulose sustained release technology
-
Hogan J.E. Hydroxypropylmethylcellulose sustained release technology. Drug Development and Industrial Pharmacy. 15:1989;975-999.
-
(1989)
Drug Development and Industrial Pharmacy
, vol.15
, pp. 975-999
-
-
Hogan, J.E.1
-
11
-
-
0029555598
-
Sensitive detection of selected cholinergic channel activators derived with 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole
-
Hui Y., Marsh K.C. Sensitive detection of selected cholinergic channel activators derived with 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole. Journal of Pharmaceutical and Biomedical Analyses. 14:1995;131-142.
-
(1995)
Journal of Pharmaceutical and Biomedical Analyses
, vol.14
, pp. 131-142
-
-
Hui, Y.1
Marsh, K.C.2
-
12
-
-
0003099518
-
-
In: Kydonieus, A. (Ed.), Marcel Dekker, New York
-
Lee, L., 1992. In: Kydonieus, A. (Ed.), Treatise on Controlled Drug Delivery: Diffusion-Controlled Matrix Systems. Marcel Dekker, New York, pp. 155-198.
-
(1992)
Treatise on Controlled Drug Delivery: Diffusion-Controlled Matrix Systems
, pp. 155-198
-
-
Lee, L.1
-
13
-
-
0000140208
-
Structure-activity studies on ABT-089: An orally bioavailable 3-pyridyl ether cholinergic channel moderator with cognitive enhancing properties
-
Lin N.H., Gunn D.E., Ryther K.B., Garvey D.S., Donnelly-Roberts D.L., Decker M.W., Brioni J.D., Buckley M.J., Rodrigues A.D., Marsh K.G., Anerson D.J., Sullivan J.P., Williams M., Arneric S.P., Holladay M.W. Structure-activity studies on ABT-089: an orally bioavailable 3-pyridyl ether cholinergic channel moderator with cognitive enhancing properties. Journal of Medicinal Chemistry. 40:1997;385-390.
-
(1997)
Journal of Medicinal Chemistry
, vol.40
, pp. 385-390
-
-
Lin, N.H.1
Gunn, D.E.2
Ryther, K.B.3
Garvey, D.S.4
Donnelly-Roberts, D.L.5
Decker, M.W.6
Brioni, J.D.7
Buckley, M.J.8
Rodrigues, A.D.9
Marsh, K.G.10
Anerson, D.J.11
Sullivan, J.P.12
Williams, M.13
Arneric, S.P.14
Holladay, M.W.15
-
14
-
-
0028270046
-
Controlled drug release of highly water-soluble pentoxifylline from time-limit disintegration-type wax matrix tablets
-
Otsuka M., Matsuda Y. Controlled drug release of highly water-soluble pentoxifylline from time-limit disintegration-type wax matrix tablets. Pharmaceutical Research. 11:1994;351-354.
-
(1994)
Pharmaceutical Research
, vol.11
, pp. 351-354
-
-
Otsuka, M.1
Matsuda, Y.2
-
15
-
-
0028902268
-
Programmable drug release of highly water-soluble pentoxifylline from dry-coated wax matrix tablets
-
Otsuka M., Matsuda Y. Programmable drug release of highly water-soluble pentoxifylline from dry-coated wax matrix tablets. Journal of Pharmaceutical Sciences. 84:1995;443-447.
-
(1995)
Journal of Pharmaceutical Sciences
, vol.84
, pp. 443-447
-
-
Otsuka, M.1
Matsuda, Y.2
-
16
-
-
0025892397
-
Design and manufacture of a zero-order sustained-release pellet dosage form through nonuniform drug distribution in a diffusional matrix
-
Scott D.C., Hollenbeck R.G. Design and manufacture of a zero-order sustained-release pellet dosage form through nonuniform drug distribution in a diffusional matrix. Pharmaceutical Research. 8:1991;156-161.
-
(1991)
Pharmaceutical Research
, vol.8
, pp. 156-161
-
-
Scott, D.C.1
Hollenbeck, R.G.2
-
17
-
-
0025147050
-
In vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms
-
Skelly J.P.et al. In vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms. Pharmaceutical Research. 7:1990;975-982.
-
(1990)
Pharmaceutical Research
, vol.7
, pp. 975-982
-
-
Skelly, J.P.1
-
18
-
-
84878761934
-
Alzheimer's disease: Prospects for treatment in the next decades
-
In: Brioni, J.D., Decker, M.W. (Eds.), Wiley-Liss, New York, 1996
-
Williams, M., Arneric, S.P., 1996. Alzheimer's disease: Prospects for treatment in the next decades. In: Brioni, J.D., Decker, M.W. (Eds.), Alzheimer's Disease. Wiley-Liss, New York, 1996.
-
(1996)
Alzheimer's Disease
-
-
Williams, M.1
Arneric, S.P.2
|